article · The Journal of Infection in Developing Countries

Efficacy of Linezolid in the management of pneumonic COVID-19 patients. Bioinformatics-based clinical study

Ragaey Ahmad Eid
Ahmed M. Sayed
Marwa O. Elgendy
Hayam M A Mostafa
Ahmed Mohammed M Elsisi
A. Hamed
Abdelrahman M. Abdallah
Marwa Abdallah Shaker

20245 citationsOpen accessBeni Suef University

Abstract

Linazolid is considered an effective antiviral weapon against SARS-COV-2. It could be used in the management plan of pneumonic individuals due to SARS-COV-2 infection. We recommend using it to combat the current wave caused by Omicron EG-5 Variant.

Research topics

SARS-CoV-2 and COVID-19 Research
COVID-19 Clinical Research Studies
Diverse Scientific Research Studies

Sustainable Development Goals

3Good Health and Well-being

Read the original research

This page summarises published work. The authoritative version sits with the publisher.

View on publisher site Record on OpenAlex

DOI: 10.3855/jidc.19205

Is something wrong with this record? Report it or request removal.

Discussion

Discuss this research

Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.

No discussion yet. Open the first thread.

New to MARATTO™? Create a free account.